Exploring reductive degradation of fluorinated pharmaceuticals using Al2O3-supported Pt-group metallic catalysts: Catalytic reactivity, reaction pathways, and toxicity assessment

Recently, an increasing number of pharmaceutical compounds has become fluorinated. Owing to their pharmacological efficacy, the use of these fluorinated pharmaceuticals continues to grow, and they constitute 20% of the drugs on the current market. However, only a few studies have investigated the fate and transformation of these emerging contaminants in natural and engineered aquatic environments. In the present study, the H-2-based reductive transformation of three fluorinated pharmaceutical compounds (levofloxacin, sitagliptin, and fluoxetine) were investigated using alumina-supported monometallic and bimetallic catalysts of the Pt-group noble metals (i.e., Ru, Rh, Pd, and Pt) under ambient temperature and pressure conditions. Degradation of all three compounds was observed with catalytic reactivity ranging from 4.0 x 10(-3) to 2.14 x 10(2) L/(min.g(cat)), in which fluoxetine generally showed the highest reactivity, followed by sitagliptin and levofloxacin. The fluorination yields and transformation products were characterized for each fluorinated compound and three different degradation mechanisms were elucidated: 1) hydrodefluorination of C-F bond to C-H bond, 2) hydrogenation of aromatic ring, and 3) reductive cleavage of C-O bond from phenyl ether. Toxicity assessment using Aliivibrio fischeri showed there were no significant changes in toxicity over levofloxacin and sitagliptin degradation, suggesting the formation of no highly toxic by-products during catalytic reduction. For fluoxetine, an increased toxicity was observed during its degradation while ECOSAR-predicted toxicity values of all identified intermediates were lower than that of fluoxetine, suggesting the formation of unidentified secondary by-products that contribute to the overall toxicity. The study showed that catalytic reduction is a promising remediation process for treating and defluorinating the fluorinated pharmaceutical compounds. (C) 2020 The Author(s). Published by Elsevier Ltd.